Elsevier

The Lancet

Volume 289, Issue 7501, 3 June 1967, Pages 1171-1174
The Lancet

ORIGINAL ARTICLES
IMMUNOLOGICAL ASPECTS OF MALIGNANT DISEASE

https://doi.org/10.1016/S0140-6736(67)92837-1Get rights and content

First page preview

First page preview
Click to open first page preview

References (6)

  • D.J. Ashley

    J. Path. Bact.

    (1965)
  • J.B. Beckwith et al.

    Am. J. Path.

    (1963)
There are more references available in the full text version of this article.

Cited by (277)

  • Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review

    2022, JACC: CardioOncology
    Citation Excerpt :

    Pexidartinib is associated with hypertension (Table 1); cardiovascular toxicities of other myeloid depletion strategies remain unknown. Although predicted as a potential antitumor treatment modality more than 50 years ago,170 clinically tractable cancer immunotherapies have become a reality only in the past decade. This achievement is based on many decades of research advances elucidating basic mechanisms of both immunity and tumorigenesis.

View all citing articles on Scopus

The Roy Cameron Memorial Lecture of the College of Pathologists, delivered in London on May 10, 1967.

View full text